Horizon’s proprietary CHOSOURCE™ platform, consisting of a GS knockout CHO K1 cell line combined with a dual promoter expression vector, is now established as an industry standard for host cell line development, faci...
Horizon Discovery CHO工程细胞系来源于ECACC(欧洲细胞库) CHO-K1 细胞,应用Horizon Discovery的重组腺病毒(rAAV)技术,通过同源重组的方式将GS基因(谷氨酰胺合成酶)第六外显子(酶催化活力必须元件)敲除,得到无谷氨酰胺合成酶的CHO-K1细胞系,进一步驯化为悬浮细胞,适应现有商业化学限定的无动物源性的培养基,从而得到...
✔ CHO K1-GS knockout cell line表达量数据支持:混合克隆一般表达量1g/L以上,单克隆一般在3g/L以上。具体信息可以参考Horizon公司网站信息: horizondiscovery.com/bi ✔ CHO K1-GS knockout cell line基因改造信息和遗传背景,2017年全基因组测序已经在Ensembl公开,可参考以下链接: asia.ensembl.org/Cricet ✔...
图6,细胞培养过程中代谢参数 由图4-6可以得知,CHO-K1细胞株在Expi CHO中的细胞生长,蛋白产量和代谢参数与Medium A相比都更优异,其中,与Medium A相比,提前两天达到最高细胞密度,最高细胞密度为18.8*106,较Medium A高36%,D14的titer为7.046g/L,比在Medium A中的提高了约10%; 此外,细胞在ExpiCHO SPM培养基...
泰诺麦博解释道:“自从2019年3月在我们的药物开发工作流程中部署CHOSOURCE CHO-K1基因敲除细胞系以来,我们已能开创先河,去开发这款针对不同疾病的mAb候选药物,包括在澳大利亚开展首项针对破伤风毒素的人类单抗I期试验。上述努力显示,部署Horizon细胞系并使其适应我们的流程是如此轻松和有效。我们对上述结果感到满意,会继...
致力于以创新技术打造更健康世界的全球领导者珀金埃尔默(PerkinElmer)日前宣布,其向珠海泰诺麦博生物技术有限公司(Trinomab Biotech. Co., Ltd.,www.trinomab.com)授权的Horizon Discovery CHOSOURCE™ CHO-K1GS敲除细胞系被用于帮助生产世界首款纯天然人单克隆中和抗体(mAb)候选药物,该药已进入抗击破伤风毒素的临床试验...
Rentschler Biopharma signed a license agreement with Horizon Discovery to use Horizon’s CHOSOURCE™ platform in combination with Rentschler’s in-house process for cell line development for difficult-to-express proteins. Horizon’s gene-edited Glutamine Synthetase (GS) knockout CHO K1 cGMP-complia...
CHO工程细胞革命Horizon Discovery CHO工程细胞系来源于ECACC(欧洲细胞库) CHO-K1 细胞,应用Horizon Discovery的重组腺病毒(rAAV)技术,通过同源重组的方式将GS基因(谷氨酰胺合成酶)第六外显子(酶催化活力必须元件)敲除,得到无谷氨酰胺合成酶的CHO-K1细胞系,进一步驯化为悬浮细胞,适应现有商业化学限定的无动物源性的...
“We are pleased to enter into this licensing agreement with NGM for this GS knockout CHO K1 cell line to support its broad research and development efforts,” said Dirk Gewert, Business Unit Director, Horizon Discovery. “Horizon aims to empower organizations of all sizes,...
ATUM has licensed Horizon’s CHO SOURCE platform, including the Glutamine Synthetase (GS) Knock-Out CHO K1 (Chinese hamster ovary) line, and will use its proprietary Leap-In®Transposase Technology to offer cell line development services. Ho...